Flugen’s universal flu vaccine development
Wednesday, September 30, 2020 7:50 PM to 8:05 PM · 15 min. (Africa/Abidjan)
Influenza & Respiratory
Platform Technology
Information
Topics
Topics
Clinical Ph 1 - 3
Infectious Diseases
Flugen
FluGen is a clinical stage vaccine company working to solve the urgent need for a more effective influenza vaccine with broader coverage and longer duration of action. The mechanism of its M2SR, single replication, intranasal flu vaccine mimics wildtype infection generating a robust and unique immune signature. Clinical studies to test M2SR’s ability to protect against substantially drifted strains are underway.
Log in
See all the content and easy-to-use features by logging in
Continue as a guest
Log in
Continue as a guest
Terrapinn UK
World Vaccine Congress Washington Virtual
Log in
Language
Organizing events?
Resource center
Contact app support
Legal notice
Terms of Use
Privacy Policy
Cookies Policy
Cookies consent
Home
WVC FULL Agenda